VRC-WEVVLP073-00-VP
Phase 1Biologic
VRC-WEVVLP073-00-VP is one of 25 biologic programs targeting Encephalitis. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
45 competitors in Encephalitis
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
Decadron
AAspen Global Incorporated
Approved
ENSPRYNG
RochePhase 3
Valtrex
GGlaxo Dba Glaxosmithkline
Phase 3
Prograf
VVeloxis Pharmaceuticals
Phase 3
Immunoglobulins
CSL BehringPhase 3
Rituxan
RochePhase 2
Biaxin
AbbViePhase 2
Daraprim
FFondazione Matilde Tettamanti Menotti De Marchi Onlus
Phase 2
UPLIZNA
HHorizon Therapeutics Ireland DAC
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Encephalitis1 trial
VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03879603·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VRC-WEVVLP073-00-VP. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details